For the industry

Project overview

This project will sustainably produce human (allogeneic) somatic stem cell materials that can be used in the manufacture of regenerative medical products in Japan.

The purpose is to establish a supply system that can provide a stable quality of cells.
In addition to Keio University Hospital, four medical institutions and companies will play a central role in this project.
Keio University Hospital has a network that will be used to provide cell materials that meet the needs of companies.
By building a system that enables a stable supply of cells while maintaining quality, we will inform the general public of the social significance of our project, and contribute to the development of the regenerative medicine industry in Japan

Initiatives of Keio University Hospital

  • Role as a procurement organization

    Keio University Hospital, as a cell procurement institution, provides tissues and cells requested by pharmaceutical companies, etc. with the consent of patients. We will establish a system to control the quality of cells so that they can be used as materials for regenerative medical products that are administered to patients. This also includes personal information management of cell donors.

  • Establishment of Keio University Hospital Human Cell Procurement Ethics Committee

    Keio University Hospital Human Cell Procurement Ethics Committee was established, and plans for procuring and providing tissues and cells at medical institutions for industrial use will be deliberated for any ethical and legal issues.

  • Information management

    Information on donated cells will be managed using the same system used for blood transfusion products.

  • Cell materials to be provided

    • Adipose tissue

    • bone marrow,etc

  • Cooperation with other medical institutions

    This project is in collaboration with Ryukyu University, which established a corporate provision system for human somatic stem cells ahead of the rest of the country.
    In the future, we will establish a network with other medical institutions through the Tokyo Metropolitan Academic Research (AR) Consortium to provide a stable source of various types of cells.